A cloud continues to loom over the implementation of the Unified Patent Convention, a system permitting a single patent covering numerous European countries, writes barrister Mark Engelman, head of intellectual property at UK-based law firm, Hardwicke, in an Expert View piece for The Pharma Letter.
A cloud not too dissimilar to that which hung over Theresa May’s seemingly unilateral decision to notify the European Union (EU) of the UK’s departure from the EU.
On that occasion, Gina Miller was seeking to stop the Brexit process starting without gaining approval from parliament, while on this occasion a German patent attorney, Ingve Björn Stjerna, is trying to prevent Germany becoming a member of the Unified Patents Convention (UPC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze